How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,005 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Androgen Insensitivity Syndrome (Diagnosis)

syndrome, the standard of care is an orchidectomy to prevent possible malignant degeneration of the testes. [ ] Next: Pathophysiology The basic etiology of androgen insensitivity syndrome is a loss-of-function mutation in the androgen receptor ( AR ) gene. This AR gene has been localized to the long arm of the X chromosome (ie, Xq11-13). Over 1,000 such mutations have been described, including complete and partial gene deletions, point mutations, and small insertions/deletions. These mutations can (...) cause a variety of functional defects, ranging from a complete loss of receptors on the cell surface because of incomplete protein synthesis to alterations in substrate binding affinity. Altered substrate binding affinity causes a signal transmission loss, despite normal cell surface receptor numbers. While the genotypes causing complete androgen insensitivity syndrome are fairly consistent in phenotypic presentation, the genotype/phenotype relationships for the mutations causing partial androgen

2014 eMedicine Pediatrics

182. Androgen Insensitivity Syndrome (Overview)

syndrome, the standard of care is an orchidectomy to prevent possible malignant degeneration of the testes. [ ] Next: Pathophysiology The basic etiology of androgen insensitivity syndrome is a loss-of-function mutation in the androgen receptor ( AR ) gene. This AR gene has been localized to the long arm of the X chromosome (ie, Xq11-13). Over 1,000 such mutations have been described, including complete and partial gene deletions, point mutations, and small insertions/deletions. These mutations can (...) cause a variety of functional defects, ranging from a complete loss of receptors on the cell surface because of incomplete protein synthesis to alterations in substrate binding affinity. Altered substrate binding affinity causes a signal transmission loss, despite normal cell surface receptor numbers. While the genotypes causing complete androgen insensitivity syndrome are fairly consistent in phenotypic presentation, the genotype/phenotype relationships for the mutations causing partial androgen

2014 eMedicine Pediatrics

183. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. (Abstract)

Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. Androgenetic alopecia (AGA) is characterized by vellus transformation of scalp hairs, corresponding to hair follicle miniaturization during repeated hair cycles with shortened anagen phase. This phenomenon is mediated mainly by androgen. Then, the multi-step molecular pathway of androgen can be involved in the pathogenesis of AGA. The expression of type II 5α-reductase is higher in dermal (...) papilla cells from AGA and beard than those from other sites. On the other hand, type I 5α-reductase expression is relatively low. Next, hormone binding assays and RT-PCR demonstrated that androgen receptor (AR) expression is significantly higher in bald dermal papilla cells than non-bald cells. Additionally, AR coactivator Hic-5/ARA55 is highly expressed in dermal papilla cells of hair follicles from androgen-sensitive sites such as AGA and beard. Collectively, the enhanced expression of type II 5α

2011 Journal of dermatological science

184. Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation of Hypothalamic-Pituitary-Adrenal Axis? Full Text available with Trip Pro

Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation of Hypothalamic-Pituitary-Adrenal Axis? 21769240 2011 11 10 2018 11 13 0974-9241 3 1 2011 Jan International journal of trichology Int J Trichology Hyposecretion of the Adrenal Androgen Dehydroepiandrosterone Sulfate (DHEA-S) in the Majority of the Alopecia Areata Patients: Is it a Primitive and Pathogenic Perturbation

2011 International journal of trichology

185. Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

, Layout table for eligibility information Ages Eligible for Study: 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year Willingness to have micro-dot-tattoo applied to scalp Willingness to maintain same hair style, length and hair color during study Exclusion Criteria: Drug or alcohol abuse within 12 months HIV positive Received hair (...) Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2011 Clinical Trials

186. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. (Abstract)

Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. When studies of postmenopausal women with hair loss failed to reveal a response to the 5 alpha reductase inhibitor, finasteride, researchers began to question the existence of androgenetic alopecia in women and renamed the clinical entity female pattern hair loss. However, recently published reports of finasteride response in some women (...) with hair loss suggest that an androgenic mechanism is mediating response in this group. Variant repeat nucleotide sequences in exon 1 of the androgen receptor (AR) gene have been shown to determine androgen sensitivity in a variety of androgenic conditions in men and women. In an effort to identify whether this AR variant may help determine which women are likely to respond to finasteride therapy, a pilot study was undertaken. In our 6-month pilot of 13 patients, women with greater androgen sensitivity

2011 Dermatologic therapy Controlled trial quality: uncertain

187. Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women

Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Androgen Excess (...) for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 32 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Study Start Date : April 2013 Estimated Primary Completion Date : June 30, 2022 Estimated Study Completion Date : June 30, 2022 Resource links provided

2013 Clinical Trials

188. Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2013 Clinical Trials

189. Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01942837 Recruitment Status : Active, not recruiting First Posted : September 16, 2013

2013 Clinical Trials

190. Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2013 Clinical Trials

191. GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01918306 Recruitment Status : Terminated (company stopped

2013 Clinical Trials

192. Androgenic alopecia

Androgenic alopecia Pattern hair loss - Wikipedia Pattern hair loss From Wikipedia, the free encyclopedia (Redirected from ) Pattern hair loss Other names Androgenic alopecia, androgenetic alopecia, male pattern baldness, female androgenic alopecia, female pattern baldness Male-pattern hair loss , Pattern hair loss , known as male-pattern hair loss ( MPHL ) when it affects males and female-pattern hair loss ( FPHL ) when it affects females, is that primarily affects the top and front (...) of 50 affects about half of males and a quarter of females. It is the most common cause of . Contents Signs and symptoms [ ] Classic male-pattern hair loss begins above the and vertex ( ) of the . As it progresses, a rim of hair at the sides and rear of the head remains. This has been referred to as a 'Hippocratic wreath', and rarely progresses to complete baldness. Pattern hair loss is classified as a form of non-scarring hair loss. The has been developed to grade androgenic alopecia in males

2012 Wikipedia

193. Androgen Replacement in Women

libido and sexual satisfaction Improves sense of well-being Appears to improve concentration and memory VII. Adverse Effects abnormalities (associated with oral androgens) tumors Cholestatic Iatrogenic Irreversible effects (Male patterned baldness) Voice deepening Clitoromegaly Reversible effects and oily skin (facial hair) Adverse effect on lipid profile Increases Decreases VIII. Causes: Secondary Causes of Hypoandrogenism Hypopituitarism Oophorectomy Secondary Medications lowering androgen levels (...) Androgen Replacement in Women Androgen Replacement in Women Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Androgen Replacement

2015 FP Notebook

194. Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

when doubled. ] Known serum testosterone ≤ 150 ng/dl or symptoms of hypogonadism (fatigue, hot flashes, hair loss, loss of muscle mass, osteoporosis, low libido, depression) prior to ADT initiation not explained by other medical co-morbidity OR history of testosterone supplement. If questionable, serum testosterone level greater than 150 ng/dl can be used to exclude hypogonadism. Previous malignancy within 3 years other than non-melanomatous skin cancer and non-muscle invasive bladder cancer (...) Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2012 Clinical Trials

195. Androgen actions on the human hair follicle: perspectives. (Abstract)

Androgen actions on the human hair follicle: perspectives. Androgens stimulate beard growth but suppress hair growth in androgenetic alopecia (AGA). This condition is known as 'androgen paradox'. Human pilosebaceous units possess enough enzymes to form the active androgens testosterone and dihydrotestosterone. In hair follicles, 5α-reductase type 1 and 2, androgen receptors (AR) and AR coactivators can regulate androgen sensitivity of dermal papillae (DP). To regulate hair growth, androgens (...) stimulate production of IGF-1 as positive mediators from beard DP cells and of TGF-β1, TGF-β2, dickkopf1 and IL-6 as negative mediators from balding DP cells. In addition, androgens enhance inducible nitric oxide synthase from occipital DP cells and stem cell factor for positive regulation of hair growth in beard and negative regulation of balding DP cells. Moreover, AGA involves crosstalk between androgen and Wnt/β-catenin signalling. Finally, recent data on susceptibility genes have provided us

2012 Experimental Dermatology

196. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Full Text available with Trip Pro

hyperandrogenism and idiopathic hirsutism.A multicenter prevalence survey included 592 consecutive premenopausal women (393 from Madrid, Spain and 199 from Bologna, Italy) reporting spontaneously for blood donation. Immediately before donation, we conducted clinical and biochemical phenotyping for androgen excess disorders. We determined the prevalence of (i) hirsutism, acne and alopecia as clinical signs of androgen excess and (ii) functional disorders of androgen excess, including PCOS, defined (...) by the National Institute of Child Health and Human Development/National Institute of Health criteria, idiopathic hyperandrogenism and idiopathic hirsutism.Regarding clinical signs of hyperandrogenism, hirsutism and acne were equally frequent [12.2% prevalence; 95% confidence interval (CI): 9.5-14.8%], whereas alopecia was uncommon (1.7% prevalence, 95% CI: 0.7-2.7%). Regarding functional disorders of androgen excess, PCOS and idiopathic hirsutism were equally frequent (5.4% prevalence, 95% CI: 3.6-7.2

2012 Human Reproduction

197. Effects of topical application of EGCG on testosterone-induced hair loss in a mouse model. (Abstract)

 < 0.05). Topical EGCG down-regulated the T-induced expression of androgen receptor but did not down-regulate 17β-hydroxysteroid dehydrogenase (HSD) and three β-HSD expression. Analysis using liquid chromatography tandem mass spectrometry (LC-MS/MS) on serum and tissue samples revealed no significant difference in T and dihydrotestosterone concentrations between the T-injected and T + EGCG groups. Thus, we found that T injection in a mouse model induces hair loss by apoptosis of the hair follicles (...) Effects of topical application of EGCG on testosterone-induced hair loss in a mouse model. We investigated the effect of topical epigallocatechin-3-gallate (EGCG) on testosterone (T)-induced hair loss in mice. Marked hair loss was observed at the T-injected site, and topical EGCG significantly reduced the hair loss (P < 0.05). TUNEL staining showed apoptosis of follicular epithelial cells in the T-injected groups where topical EGCG was found to significantly diminish T-induced apoptosis (P

2011 Experimental Dermatology

198. Alopecia

variant of lichen planopilaris. Etiology The alopecias comprise a large group of disorders with multiple and varying etiologies ( ). The most common cause of alopecia is Androgenetic alopecia (male-pattern or female-pattern hair loss) Androgenetic alopecia is an androgen-dependent hereditary disorder in which dihydrotestosterone plays a major role. This form of alopecia may eventually affect up to 80% of white men by the age of 70 (male-pattern hair loss) and about half of all women (female-pattern (...) number of broken hairs. Primary hair shaft abnormalities are usually obvious on microscopic examination of the hair shaft. Scalp biopsy is indicated when alopecia persists and diagnosis is in doubt. Biopsy may differentiate scarring from nonscarring forms. Specimens should be taken from areas of active inflammation, ideally at the border of a bald patch. Fungal and bacterial cultures may be useful. Daily hair counts can be done by the patient to quantify hair loss when the pull test is negative

2013 Merck Manual (19th Edition)

199. Androgenetic Alopecia in Fabry Disease

is to assess whether patients with the classic form of Fabry disease have significantly less androgenic alopecia (male pattern baldness). Condition or disease Fabry Disease Detailed Description: Objectives: To test the hypothesis that adult males with classic form of Fabry disease have a significantly lower incidence of androgenic alopecia than matched controls. Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual (...) enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls. Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects. Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment

2011 Clinical Trials

200. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. (Abstract)

Androgenetic alopecia as an early marker of benign prostatic hyperplasia. Androgenetic alopecia (AGA) and benign prostatic hyperplasia are both androgen-dependent entities that respond to the blocking of 5-alpha-reductase.The objective of this study was to determine whether prostatic volumes and urinary flow changes were higher in patients with early-onset AGA than in healthy control subjects.This was an observational case-control study of 87 men: 45 with early-onset AGA diagnosed

2011 Journal of American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>